Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31675131 | 1.00 | RIPK1 (0.49) | RIPK1GABRA1GABRB2CES2CES1 | |
| SCHEMBL22306130 | 0.87 | GABRA1 (0.55) | RIPK1GABRA1GABRB2KAT6A | |
| SCHEMBL424618 | 0.85 | CES2 (0.43) | RIPK1CES2CES1BCHEAKR1B1 | |
| SCHEMBL5610129 | 0.81 | TAAR1 (0.41) | RIPK1CES2CES1BCHEAKR1B1 | |
| SCHEMBL4476574 | 0.81 | RIPK1 (0.42) | RIPK1GABRA1GABRB2CES2CES1 | |
| SCHEMBL14640304 | 0.80 | TAAR1 (0.39) | RIPK1CES2CES1BCHEAKR1B1 | |
| SCHEMBL138361 | 0.79 | — | — | |
| SCHEMBL29943841 | 0.79 | — | — | |
| SCHEMBL7052559 | 0.79 | TAAR1 (0.48) | RIPK1CES2CES1BCHEAKR1B1 | |
| SCHEMBL3300692 | 0.79 | MPO (0.47) | RIPK1GABRA1GABRB2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11807648-B2 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | SHIONOGI & CO., LTD. (JP) | 2023-11-07 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230265110-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| EP-4219453-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6066646-A | INSECTICIDAL, ACARICIDAL OR NEMATICIDAL COMPOSITION | ZENECA LIMITED (GB) | 2000-05-23 | — | — | US | disclosed |
| US-5912254-A | BIS(8-AZABICYCLO(3.2.1)OCTANE) DERIVATIVES, PESTICIDES | ZENECA LIMITED (GB) | 1999-06-15 | — | — | US | disclosed |
| EP-0363458-B1 | 2,3-DIFLUOROBENZENES | MERCK PATENT GMBH (DE) | 1994-08-03 | — | — | EP | disclosed |
| US-5087764-A | Deprotonation of a 1-substituted-2,3-difluorobenzene using an organometallic compound and reacting the reaction product with an electrophile | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 1992-02-11 | — | — | US | disclosed |
| EP-0400068-A1 | DERIVATIVES OF 2,3-DIFLUOROPHENOL | MERCK PATENT GmbH (DE) | 1990-12-05 | — | — | EP | disclosed |
| EP-0363458-A1 | 2,3-DIFLUOROBENZENES. | MERCK PATENT GMBH (DE) | 1990-04-18 | — | — | EP | disclosed |
| WO-1989008629-A1 | PROCESS FOR PREPARING 2,3-DIFLUOROBENZENES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| WO-1989008632-A1 | DERIVATIVES OF 2,3-DIFLUOROPHENOL | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807648-B2 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | REN, C5, PDXK | RIPK1 1307/4885GABRA1 3670/4885GABRB2 4382/4885 |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885GABRA1 2762/4885GABRB2 2643/4885 |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | TYMP, TYMS, DPYD | RIPK1 2636/4885GABRA1 3968/4885GABRB2 3798/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | RIPK1 2645/4885GABRA1 3865/4885GABRB2 3638/4885 |
| US-20230265110-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | RIPK1 2308/4885GABRA1 3786/4885GABRB2 4020/4885 |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | ERG28, UGCG, DPM1 | RIPK1 450/4885GABRA1 4267/4885GABRB2 4026/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | RIPK1 827/4885GABRA1 2605/4885GABRB2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.